Life sciences companies face rising supply chain and geopolitical risks

The life sciences industry is navigating a period of increased complexity driven by geopolitical uncertainty, shifting trade routes, and new tariff structures. Companies are moving away from supply chain models optimized solely for low cost toward strategies focused on building resilience and adaptability.

To manage these challenges, organizations are adopting technological innovations such as artificial intelligence for demand forecasting, digital twins, advanced serialization, and automated logistics. These tools aim to improve real-time visibility, product traceability, and predictive planning for complex products like biologics and gene therapies.

However, industry experts note that technology alone is insufficient. Success requires addressing data quality, supplier dependencies, regulatory requirements, and cybersecurity to ensure product integrity and responsiveness during disruptions.